PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma
Status:
Terminated
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
This is a phase II open label study to assess the efficacy and safety of PTK787/ZK222584 in
adults with relapsed or refractory diffuse large cell lymphoma (DLCL). All subjects will
receive PTK787/ZK222584. Subjects who tolerate the study target dose of 1250mg will remain on
that dose until study completion at 12 months or until disease progression, unacceptable
toxicity, withdrawal of consent or non-compliance with the protocol requirement.